Chronic lung diseases that cause scarring of lung tissue are among the most challenging conditions in respiratory medicine. Once scarring begins, it cannot be reversed, so treatment focuses on slowing its progression and preserving lung function for as long as possible. Nintedanib 150 mg is one of the most widely used antifibrotic therapies for this purpose. Biophar Lifesciences supports access to quality Nintedanib 150 mg for patients and healthcare providers who manage these conditions.
What Is Nintedanib?
Nintedanib is an oral antifibrotic medicine belonging to the class of tyrosine kinase inhibitors. It blocks several receptors involved in the growth and activity of fibroblasts, the cells responsible for producing scar tissue in the lungs. These include the platelet-derived growth factor receptor (PDGFR), the fibroblast growth factor receptor (FGFR) and the vascular endothelial growth factor receptor (VEGFR). By interfering with these signaling pathways, Nintedanib helps slow the buildup of fibrotic tissue and the decline in lung function that follows.
Nintedanib does not cure fibrosis or reverse existing lung damage. Its role is to slow the disease, which can help patients maintain their breathing capacity and quality of life for longer.
Approved Uses of Nintedanib 150 mg
Nintedanib 150 mg is generally prescribed for the following conditions:
- Idiopathic Pulmonary Fibrosis (IPF): A progressive lung disease of unknown cause, in which the lung tissue becomes thick and stiff, making breathing increasingly difficult.
- Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): Lung scarring that develops in people with systemic sclerosis, an autoimmune connective tissue disorder.
- Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype: Other fibrosing lung conditions that continue to worsen over time despite standard care.
In some regions, Nintedanib is also approved alongside chemotherapy for certain types of non-small cell lung cancer. Approved indications vary by country, so patients should always follow the guidance of their treating physician.
Recommended Dosage
The usual adult dose of Nintedanib is 150 mg taken twice daily, roughly 12 hours apart. Key points include:
- Capsules should be swallowed whole with liquid and taken with food, which can help reduce stomach-related side effects.
- Capsules should not be chewed or crushed.
- If a dose is missed, the next dose should be taken at the regular time. Patients should not double up.
- A lower dose of 100 mg twice daily may be prescribed for patients with mild liver impairment or those who have trouble tolerating the standard dose.
Doctors may temporarily interrupt or reduce the dose to manage side effects, so dose changes should only ever be made under medical supervision.
Benefits of Nintedanib Therapy
Clinical studies of Nintedanib in IPF and progressive fibrosing lung disease have shown that it significantly reduces the annual rate of decline in forced vital capacity (FVC), a key measure of how much air a person can forcefully exhale. Slowing this decline matters because a steady loss of lung capacity leads to worsening breathlessness, reduced activity and a poorer quality of life.
Studies have also linked antifibrotic therapy to fewer acute exacerbations in some patient groups, though results vary between individuals. Because fibrotic lung disease is progressive, starting treatment early, once the diagnosis is confirmed, is often considered beneficial.
Common Side Effects
Like all medicines, Nintedanib can cause side effects. The most commonly reported include:
- Diarrhea, which is the most frequent and is usually manageable with hydration and anti-diarrheal medication
- Nausea and vomiting
- Abdominal pain
- Decreased appetite and weight loss
- Elevated liver enzymes
Less commonly, patients may experience bleeding problems or, rarely, blood clot-related events. Anyone who notices persistent or severe symptoms, such as continuous diarrhea, yellowing of the skin or eyes, or unusual bleeding, should contact their doctor promptly.
Important Precautions
Before starting Nintedanib 150 mg, patients should discuss their full medical history with their doctor. Special care is needed in these situations:
- Liver function: Liver tests are usually done before treatment starts and monitored regularly afterward.
- Pregnancy and breastfeeding: Nintedanib may harm an unborn baby. Effective contraception is advised during treatment and for a period after the last dose, and it is not recommended during breastfeeding.
- Cardiovascular and bleeding risk: Patients with heart disease, a history of blood clots or a tendency to bleed need careful evaluation.
- Drug interactions: Some medicines, including certain antifungals, antibiotics and anticonvulsants, can alter Nintedanib levels in the body. Patients should tell their doctor about everything they take, including supplements.
- Smoking: Smoking can reduce the effectiveness of Nintedanib, and quitting is strongly encouraged.
Supporting Patients with Quality Medicines
Consistent, uninterrupted treatment is essential for anyone living with progressive lung fibrosis. Reliable access to properly manufactured, quality-controlled medicines helps patients stay on therapy as prescribed. Biophar Lifesciences is committed to supporting healthcare professionals and patients with dependable pharmaceutical products, including Nintedanib 150 mg.
Final Thoughts
Nintedanib 150 mg is an important option for slowing the progression of pulmonary fibrosis and related interstitial lung diseases. While it cannot reverse existing damage, it can help preserve lung function and support a better quality of life when used correctly and monitored regularly.
This article is for informational purposes only and is not a substitute for professional medical advice. Nintedanib is a prescription medicine and should be used only under the supervision of a qualified healthcare professional.
Comments